I-03 Pascal Schulthess Frequency-domain derived optimisation of cell cycle specific cancer treatment Wednesday 10:10-11:40 |
I-07 Shringi Sharma A Joint Model to Evaluate the Relationship between Lymph Node Response and Progression-Free Survival in Chronic Lymphocytic Leukemia Wednesday 10:10-11:40 |
I-08 Dmitry Shchelokov A semi-mechanistic model of targeted therapy for melanoma Wednesday 10:10-11:40 |
I-20 Mark Stroh Customizing the distribution of a masked, tumor-activated antibody with quantitative systems pharmacology Wednesday 10:10-11:40 |
I-28 Sonya Chapman Dose Fractionation Study Design and PK/PD Model Analysis to Establish the Quantitative Pharmacology of Selective Aurora A Kinase Inhibition by Compound X and LY3295668 Wednesday 10:10-11:40 |
I-52 Johan Wallin Validation of Xenograft Dose Predictions for Clinical Efficacy in NSCLC Wednesday 10:10-11:40 |
I-59 Justin Wilkins Population pharmacokinetic analysis of M7824 (MSB0011359C) in different cancer types Wednesday 10:10-11:40 |
I-60 Francis Williams Ojara A time-to-event analysis of paclitaxel-related peripheral neuropathy in patients with advanced non-small cell lung cancer receiving first line chemotherapy Wednesday 10:10-11:40 |
I-63 Gudrun Wuerthwein Population pharmacokinetics for PEGylated asparaginase Oncaspar® in children with ALL: differences between protocol parts and predictivity Wednesday 10:10-11:40 |
I-65 Feifan Xie A model-based analysis of the kinetics of leukocytes in stage III ovarian cancer patients treated with neo-adjuvant chemotherapy, cytoreductive surgery and cisplatin-based intraperitoneal chemoperfusion Wednesday 10:10-11:40 |
II-08 Yan Feng A Mixture Tumor Growth Dynamic (TGD) Model to Describe Differential Patterns of Longitudinal Tumor Response of Advanced Melanoma Patients Treated with Ipilimumab Wednesday 15:50-17:20 |
II-09 Fernandez Teruel Carlos Drug exposure / response model for neutropenia with lurbinectedin in cancer patients Wednesday 15:50-17:20 |
II-15 Matthias Frei Distinguishing myelosupressive response of a paclitaxel –radium-223 combination using a model-based analysis of an individual cross-over phase-Ib trial in cancer patients with bone lesions Wednesday 15:50-17:20 |
II-22 Glenn Gauderat Reversing resistance to anticancer treatment supported by pharmacokinetic/pharmacodynamic modeling of tumor growth kinetics in xenograft mice Wednesday 15:50-17:20 |
II-46 Joy Hsu Population Pharmacokinetic and Exposure-Efficacy/Safety Analyses for the Confirmation of Alectinib 600 mg BID Dose Regimen in the Global ALK Inhibitor-Naïve Population Wednesday 15:50-17:20 |
II-52 Julie Janssen Semi-physiological Pharmacokinetics of Bortezomib in Pediatric Patients with Acute Lymphoblastic Leukemia Wednesday 15:50-17:20 |
II-57 Martin Johnson Artificial neural networks can facilitate the analysis and prediction of longitudinal tumour size data: an example from a non-small cell lung cancer phase III study Wednesday 15:50-17:20 |
II-63 Astrid Jullion Dosing Regimen selection supported by population PKPD model of thrombocytopenia Wednesday 15:50-17:20 |
II-64 Yunseob Jung A population pharmacokinetic model of methotrexate in Korean people Wednesday 15:50-17:20 |
II-69 Yuri Kheifetz Integral individualized model of hematopoiesis explains and predicts joint dynamics of thrombocytes, granulocytes and lymphocytes under different chemotherapeutic and adjuvant treatments scenarios Wednesday 15:50-17:20 |
III-15 Guillaume Baneyx Target-mediated drug disposition modeling of lacnotuzumab in healthy volunteers and patients with advanced malignancies and triple negative breast cancer. Thursday 09:55-11:30 |
III-36 Tim Cardilin Modeling of radiation therapy and radiosensitizing agents in tumor xenografts Thursday 09:55-11:30 |
III-37 Evelina Cardoso Population pharmacokinetic analysis of erlotinib in cancer patients affected by NSCLC Thursday 09:55-11:30 |
III-41 Anne Chain Extension of population pharmacokinetic analysis of pembrolizumab to paediatric patients patients with classical Hodgkin lymphoma Thursday 09:55-11:30 |
III-46 Wenjun Chen Modeling the antitumor efficacy and pharmacokinetic/pharmacodynamic interaction between docetaxel and cabozantinib in human prostate cancer xenograft mouse models Thursday 09:55-11:30 |
III-66 Elien De Thaye In vitro data supporting circulating CCCK18 as potential pharmacodynamic biomarker in ovarian cancer Thursday 09:55-11:30 |
III-67 Aurelia de Vries Schultink Therapeutic drug monitoring of endoxifen in ER-positive breast cancer patients: comparing data from clinical practice to model-based predictions. Thursday 09:55-11:30 |
III-70 Oleg Demin Jr Quantitative Systems Pharmacology Modeling of CAR-T Therapy and T Cell Engaging Bispecific Antibodies: B-cell Acute Lymphoblastic Leukemia Case Study Thursday 09:55-11:30 |
III-73 Anne-Gaelle Dosne Optimizing Biomarker-Based Dosing Algorithm for Erdafitinib through PK-PD Modeling and Simulations Thursday 09:55-11:30 |
III-75 Vincent Dubois Comparative attributes of a semimechanistic and an empirical population PK model for durvalumab, a fully human anti-PD-L1 monoclonal antibody Thursday 09:55-11:30 |
III-76 Miro Eigenmann Dynamic in vitro PKPD assessment to improve pharmacological response profiling of T-cell bispecifics Thursday 09:55-11:30 |
IV-16 Rubin Lubomirov Population pharmacokinetic-based targeted exome sequencing (PopPK-TES) approach to assess the impact of genetic variants on pharmacokinetics of lurbinectedin in patients with advanced cancer Thursday 15:10-16:40 |
IV-17 Sreenath M Krishnan Accuracy in the estimation of the hazard in simultaneous and sequential estimation approaches of tumor size and overall survival (OS) modeling Thursday 15:10-16:40 |
IV-27 Christophe Meille PKPD modeling of preclinical anti-tumor activity translates to first-in-human phase I study of MDM2 inhibitor HDM201 Thursday 15:10-16:40 |
IV-31 Jonathan Mochel Modeling Primary Tumor Growth in a Xenograft Mouse Model of Non-Small Cell Lung Cancer Treated With Pemetrexed-Cisplatin and Bevacizumab Thursday 15:10-16:40 |
IV-34 Ricardo Nalda-Molina Population Pharmacokinetics of Hyperthermic Intraoperative Peritoneal Oxaliplatin in Wistar Rats Thursday 15:10-16:40 |
IV-35 Antonina Nikitich Immune Response Template for Quantitative Systems Pharmacology Modeling: Description of Co-inhibitory and Co-stimulatory Receptors Interaction Thursday 15:10-16:40 |
IV-39 Ana Novakovic Simulation based assessment of flat dose regimen of an anti-PDL1 antibody: Case study of avelumab Thursday 15:10-16:40 |
IV-41 Katharina Och A pharmacokinetic/pharmacodynamic model of cyclosporine A and its nephrotoxicity in patients after hematopoietic stem cell transplantation Thursday 15:10-16:40 |
IV-65 Alicja Puszkiel Quantitative evaluation of the impact of CYP2D6 genetic polymorphisms on pharmacokinetics of tamoxifen and its metabolites in breast cancer patients Thursday 15:10-16:40 |